Compugen (CGEN) Capital Expenditures (2009 - 2010)
Compugen (CGEN) posted quarterly Capital Expenditures of $88000.0 for Q4 2010, up 23.94% year-over-year from $71000.0 in Q4 2009, and up 344.44% on a QoQ basis from -$36000.0 in Q3 2010.
Compugen (CGEN) Capital Expenditures (2009 - 2010) Analysis & Trends
Compugen has reported Capital Expenditures for 2 years, with the latest figure at $88000.0 in Q4 2010.
- Capital Expenditures for Q4 2010 came in at $88000.0, up 23.94% year-over-year; the trailing twelve-month figure through Dec 2010 was $112000.0 (changed N/A YoY), and the FY2025 annual result was $306000.0, up 159.32% from the prior year.
- Capital Expenditures advanced to $88000.0 in Q4 2010, from -$36000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $88000.0 in Q4 2010 and troughed at -$36000.0 in Q3 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Compugen | 227.88 Mn | 136.13 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 88,000.00 |
| Dec 31, 2010 | 88,000.00 |
| Sep 30, 2010 | -36,000.00 |
| Sep 30, 2010 | -36,000.00 |
| Dec 31, 2009 | 71,000.00 |
| Dec 31, 2009 | 71,000.00 |
| Sep 30, 2009 | -11,000.00 |
| Sep 30, 2009 | -11,000.00 |